Vitality Watch

Dossier pubmed preclinical 10-aug-2026
Animal model, organoid, or cell-culture result — not yet human

Fibrillarin Resists Cellular Senescence Via SIRT1-Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma.

Key claim: Fibrillarin resists cellular senescence by stabilizing SIRT1 and sustaining nicotinamide metabolism, and inhibiting FBL sensitizes senolytic therapy in esophageal squamous cell carcinoma.

Abstract

The importance of fibrillarin (FBL), an established nucleolar methyltransferase, was identified in neoplastic growth of esophageal squamous cell carcinoma (ESCC), one of the most lethal malignancies worldwide. However, the underlying mechanism remains unclear. Here, by enrolling independent ESCC cohorts, we verified the negative correlation between intratumoral FBL expression and patient prognosis. Notably, comprehensive transcriptomic and metabolomic analyses indicated that FBL deletion elicited cell cycle arrest and cellular senescence, as well as block of nicotinamide metabolism and increase of oxidative stress. Mechanistically, FBL could bind to and stabilize SIRT1 by obstructing the ubiquitin-proteasome-mediated protein degradation, therefore provoking nicotinamide metabolism, sustaining redox homeostasis, and counteracting senescence. Clinically, FBL-SIRT1 axis was augmented in tumor tissues of ESCC patients, and high intratumoral SIRT1 expression predicted poor patient survival. Finally, we found that both genetic and pharmacological inhibition of FBL could sensitize senolytic therapy for ESCC. In conclusion, we first discovered FBL as an anti-senescent protein in tumor progression. FBL resists cellular senescence by stabilizing SIRT1 and sustaining the nicotinamide metabolism, therefore providing an optional strategy for ESCC treatment by sensitizing senolytic therapy with FBL inhibitors.

Why this matters

The finding inserts a nucleolar rRNA-modifying enzyme (fibrillarin) upstream of SIRT1 stability and nicotinamide metabolism as a determinant of whether cells resist senescence, expanding the SIRT1 regulatory map beyond PTMs and cofactors into ribosome-biogenesis machinery. In an ESCC context it recasts FBL inhibition as a senolytic sensitizer, illustrating the dual-use tension where a pro-senescence lever is therapeutically desirable in cancer but would run opposite to anti-senescence goals in healthspan biology. Translation status is preclinical cancer cells only — no aging outcome data.

Source

Link

Briefing card

Fibrillarin Resists Cellular Senescence Via SIRT1-Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma.
Stage: preclinical · pubmed · 10-aug-2026

Fibrillarin resists cellular senescence by stabilizing SIRT1 and sustaining nicotinamide metabolism, and inhibiting FBL sensitizes senolytic therapy in esophageal squamous cell carcinoma.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1002/advs.76962

build build 880 · 2bcef25 · 2026-11-18